

p^t February, 2019

ept. of Corporate Services
BSE Ltd.

PJ Towers, Dalal Street,

Mumbai - 400 001.

BSE Scrip Code: 524735

Dear Sir,

Listing Department

National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex

Bandra (East) Mumbai 400051.

NSE Symbol: HIKAL

Subject: Intimation pursuant to Securities and Exchange Board of India (Listing

Obligation and Disclosure Requirements) Regulations, 2015

With ref rence to the above, we hereby submit/inf rm as under:

A. Unaudited Financial Results [Regulation33]

The Board of Directors at its meeting held on 1st February, 2019, which commenced at 11.30 am and concluded at 02.15 pm. has approved and taken on record Standalone. Unaudited Financial Results of the Company f r the Quarter ended 31st December, 2018.

- The Standalone Unaudited Financial Results of the Company for the Quarter ended 3pt December, 2018 along with Limited Review Report are enclosed herewith in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015.
- B. Dividend, Record Date and Payment Date [Regulation 42 and 43]
- 3. The Board of Directors has declared an Interim Dividend f r the f na cial year 2018-19 on Equity Share Capital@ 30% [Rs.0.60 per equity share, nominal value of Rs. 2/each] at their meeting held on 1st February, 2019.

Hikal Ltd.

- The Company has fixed Record Date as Thursday, 14th February, 2019 to ascertain the shareholders of the Company entitled for the payment of Interim Dividend.
- 5 The Interim Dividend will be paid to the shareholder on 22nd February, 2019.

We request you to kindly take same on your record.

Thanking you,

Yours faithfully, for **HIKAL LTD.**,

Sham Wahalekar Sr. V.P. Finance & Company Secretary

Hikal Ltd.





Q3 -YoY Revenue up by 17% and PAT up by 26% Nine months -YoY Revenue up by 24% and PAT up by 34%

Extract of unaudited financial results for the quarter and nine months ended 31 December 2018

Rs. In Lakhs (Except for per share data)

		Audited					
Particulars	Q	uarter ended		Nine months ended		Year ended	
	31-Dec-18	30-Sep-18	31-Dec-17	31-Dec-18	31-Dec-17	31-Mar-18	
Total income	41,220	39,515	35,150	1,13,432	91,244	1,30,455	
Net Profit for the period (before tax, Exceptional and/or Extraordinary item)	4,196	3,554	3,436	10,094	7,231	11,150	
Net Profit for the period before tax (after Exceptional and/or Extraordinary item)	4,196	3,554	3,436	10,094	7,231	11,150	
Net Profit for the period after tax (after Exceptional and/or Extraordinary item)	2,938	2,443	2,324	6,975	5,189	7,723	
Total Comprehensive Income for the period [Comprising profit for the period (after tax) and Other Comprehensive income (after tax)]	2,934	2,441	2,312	6,968	5,152	7,726	
Equity share capital Other equity Earnings Per Share (Face Value of Rs 2/- each) (for continuing and discontinued operations) (Refer note 3)	2,466	2,466	1,644	2,466	1,644	1,644 65,295	
- Basic - Diluted - Cash	2.38 2.38 4.29	1.98 1.98 3.89	1.88 1.88 3.62	5.65 5.65 11.30	4.18 4.18 9.38	6.27 6.27 13.21	

Note

- 1. The above is an extract of the detailed format of quarterly financial results filed with the stock exchanges under regulation 33 of the SEBI (Listing Obligations and Requirements) Regulations, 2015. The full format of the financial results are available on the stock exchange websites (www.bseindia.com and www.nseindia.com) and Company's website (www.hikal.com).
- 2. The Board of Directors have declared interim dividend of 30 %(Re 0.60 per share)(Previous year 35%) on equity shares.
- 3. The Company has alloted 4,11,00,250 equity shares as fully paid up bonus shares by capitalisation of securities premium of Rs 822 lakhs, pursuant to an ordinary passed at the extra-ordinary general meeting.

earning per share (EPS) have been restated to give effect of bonus shares allotted on 26

as required by Ind AS 33.

The figures for the previous periods have been regrouped whenever necessary.

For HIKAL LTD

9 --

Place: Mumbai

Date : 1 February 2019

Jai Hiremath
Chairman and Managing Director
DIN: 00062203

HIKAL LTD

Regd. Office: 717/718, Maker Chamber V, Nariman Point, Mumbai - 400 021.

Phone: +91-22-30973100, Fax: +91-22-30973281

CIN: L24200MH1988PTC048028, E Mail: info@hikal.com , Website: www.hikal.com

Just the

Statement of unaudited financial results for the quarter and nine months ended 31 December 2018

Rs. In Lakhs (Except for per share data) Unaudited Audited Quarter ended Nine months ended Year ended **Particulars** 31-Dec-18 31-Dec-18 31-Dec-17 30-Sep-18 31-Dec-17 31-Mar-18 Revenue from operations Sale of products 40,537 38,900 34,660 1,11,616 89,886 1 28,234 Other operating revenues 630 584 1,595 403 1,074 1,775 Total revenue from operations 41,167 39,484 35,063 1,13,211 90,960 1,30,009 Other income 53 284 446 Total revenue 41,220 39,515 35,150 1,13,432 91,244 1,30,455 Expenses Cost of materials consumed 23,598 20,044 20,380 60,318 49,976 71,532 Changes in inventories of finished goods and work-in-progress (1,296)536 (1,634)-825 (963)(1,857)Excise duty on sale of goods 399 399 Employee benefits expense 3,932 3,861 3,260 11,414 9,593 12,805 Finance costs (Refer note 4) 1,336 1,642 1,190 4,579 3,665 4,912 Depreciation and amortisation expenses 2,352 2,355 2,147 6.965 6.418 8,559 Other expenses 7,102 7,523 5,562 21,025 15,819 22,732 Total expenses 37,024 35,961 31,714 1,03,338 84,013 1,19,305 Profit from ordinary activities before tax and exceptional item 3,554 4,196 3,436 10,094 7,231 11,150 Exceptional item Profit before tax 4,196 3,554 3,436 10.094 7,231 11,150 Tax expense: -Current tax 1,306 1,244 1,292 3,338 2,611 4,473 -Deferred tax (180)(133)(48)(219)(1,046)(569)Total tax expense 1,258 1,111 1,112 3,119 2,042 3,427 Profit for the period 2,938 2,443 2,324 6,975 5,189 7,723 Other comprehensive income (OCI) Items to be reclassified to statement profit and loss Income tax relating to items that will be reclassified to statement of Items that will not be reclassified to statement of profit and loss (5) (3)(19)(10)(56)6 Income tax relating to item that will not be reclassified to statement of profit and loss 3 19 (3) Total comprehensive income 2,934 2,441 2,312 6,968 5,152 7,726 Paid-up equity share capital (Face value of Rs 2 each) 2,466 2,466 1,644 2,466 1,644 1,644 65,295 Earnings Per Share (Face Value of Rs 2/- each) (Refer note 5) - Basic 1.98 2.38 1.88 5.65 4.18 6.27 - Diluted 2.38 1.98 1.88 5.65 4.18 6.27 - Cash 3.89 3.62 4.29 11.30 9.38 13.21

Notes:

- 1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting on 1 February 2019.
- 2. The Board of Directors have declared interim dividend of 30% (Re 0.60 per share)(Previous year 35%) on equity shares.
- 3. The financial results for the quarter and nine months ended on 31 December 2018 have been subjected to a 'Limited Review' by the statutory auditors of the Company. The statutory auditors have expressed an unqualifed opinion. The limited review report will be filed with the stock exchanges and will also be available on the Company's website, www.hikal.com.
- 4.Finance cost for the quarter ended 31 December 2018 includes exchange gain on foreign currency working capital/term loans of Rs. 78 lakhs. (Quarter ended 30 September 2018 loss of Rs 385 lakhs, quarter ended 31 December 2017 Rs Nil) and loss of Rs 761 lakhs for the nine months ended 31 December 2018. (Rs Nil for the nine months ended on 31 December 2017 and Rs 69 lakhs for the year ended 31 March 2018).
- 5. The Company has alloted 4,11,00,250 equity shares as fully paid up bonus shares by capitalisation of securities premium of Rs 822 lakhs, pursuant to an ordinary resoluation passed at the extra-ordinary general meeting.

The earning per share (EPS) have been restated to give effect of bonus shares allotted on 26 June 2018, as required by Ind AS 33.

- 6. Effective 1 July 2017, sales are recorded net of GST whereas earlier sales were recorded gross of excise duty which form part of expenses. Hence revenue from operations for the nine months ended 31 December 2018 are not comparable with previous period corrosponding figures.
- 7. Effective 1 April 2018, the Company has adopted Ind AS 115, 'Revenue from contracts with customers'. Based on the assessment done by the management there is no material impact on the revenue recognised during the period ended 31 December 2018.

8. The figures for the previous periods have been regrouped whenever necessary.

Place : Mumbai

Date : 1 February 2019

Aports Mall Derrysans, Multistactil, Mumbal-400711, India

THE WORLD

Jal Hiremath

For HIKAL

Chairman and Managing Director DIN: 00062203

HIKAL LTD

Regd. Office: 717/718, Maker Chamber V, Nariman Point, Mumbai - 400 021.

Phone: +91-22-30973100, Fax: +91-22-30973281

CIN: L24200MH1988PTC048028, E Mail: info@hikal.com, Website: www.hikal.com

Just the right chemistry





Segment wise revenue, results, assets, liabilities and capital employed for the quarter and nine months ended 31 December 2018

(Rs in Lakhs)

Particulars . Segment Revenue a) Pharmaceuticals b) Crop protection products Total Less: Inter segment revenue Revenue from operations . Segment Results Profit before interest and tax a) Pharmaceuticals b) Crop protection products Total Less:	31-Dec-18 25,209 15,958	25,092 14,392 39,484	21,189 13,874 35,063	45,212		Audited Year ended 31-Mar-18 75,281 54,728 1,30,009
. Segment Revenue a) Pharmaceuticals b) Crop protection products Total Less: Inter segment revenue Revenue from operations . Segment Results Profit before interest and tax a) Pharmaceuticals b) Crop protection products Total Less:	31-Dec-18 25,209 15,958 41,167	25,092 14,392 39,484	31-Dec-17 21,189 13,874 35,063	31-Dec-18 67,999 45,212	31-Dec-17 53,812 37,148	31-Mar-18 75,281 54,728
a) Pharmaceuticals b) Crop protection products Total Less: Inter segment revenue Revenue from operations Segment Results Profit before interest and tax a) Pharmaceuticals b) Crop protection products Total Less:	25,209 15,958 41,167	25,092 14,392 39,484	21,189 13,874 35,063	67,999 45,212	53,812 37,148	75,281 54,728
a) Pharmaceuticals b) Crop protection products Total Less: Inter segment revenue Revenue from operations Segment Results Profit before interest and tax a) Pharmaceuticals b) Crop protection products Total Less:	15,958 41,167	14,392 39,484	13,874 35,063	45,212	37,148	54,728
a) Pharmaceuticals b) Crop protection products Total Less: Inter segment revenue Revenue from operations Segment Results Profit before interest and tax a) Pharmaceuticals b) Crop protection products Total Less:	15,958 41,167	14,392 39,484	13,874 35,063	45,212	37,148	54,728
Total Less: Inter segment revenue Revenue from operations Segment Results Profit before interest and tax a) Pharmaceuticals b) Crop protection products Total Less:	15,958 41,167	14,392 39,484	13,874 35,063	45,212	37,148	54,728
Total Less: Inter segment revenue Revenue from operations Segment Results Profit before interest and tax a) Pharmaceuticals b) Crop protection products Total Less:	41,167	39,484	35,063			
Revenue from operations Segment Results Profit before interest and tax a) Pharmaceuticals b) Crop protection products Total Less:	41,167					
. Segment Results Profit before interest and tax a) Pharmaceuticals b) Crop protection products Total Less:	41,167	39,484)#0	
Profit before interest and tax a) Pharmaceuticals b) Crop protection products Total Less:	41.5		35,063	1,13,211	90,960	1,30,00
Profit before interest and tax a) Pharmaceuticals b) Crop protection products Total Less:						
a) Pharmaceuticals b) Crop protection products Total Less:						
b) Crop protection products Total Less:	3,335	3,502	2,704	9,018	6,803	9,85
Total Less:	3,185	2,494	2,704	8,151	5,428	9,65 8,65
Less:	6,520	5,996	4,952	17,169	12,231	18,507
i) Finance and	0,020	2,770	1,732	17,107	12,231	10,307
i) Finance cost	1,336	1,642	1,190	4,579	3,665	4,91
ii) Other un-allocable expenditure	1,041	826	398	2,641	1,567	2,75
Add:					.,	_,
i) Other un-allocable income	53	26	72	145	232	305
Profit before tax	4,196	3,554	3,436	10,094	7,231	11,150
. Segment assets	16					
a) Pharmaceuticals	1,03,413	99,131	04.405	4 02 442	04.405	00.44
b) Crop protection products	57,217	99,131 52,077	91,125 51,592	1,03,413 57,217	91,125	92,14
c) Unallocated	13,018	12,676	8,761	13,018	51,592 8,761	53,04
Total segment assets		1,63,884	1,51,478	1,73,648	1,51,478	8,98 1,54,17
Segment liabilities	1,75,040	1,05,004	1,31,470	1,73,040	1,31,476	1,54,17
a) Pharmaceuticals	22,613	21,698	19,334	22,613	19,334	16,86
b) Crop protection products	22,113	16,990	16,525	22,113	16,525	18,38
c) Unallocated	55,752	54,971	50,503	55,752	50,503	51,98
Total segment liabilities	1,00,478	93,659	86,362	1,00,478	86,362	87,23
. Capital Employed	. = 0, 1					,
a) Pharmaceuticals	80,800	77,433	71,791	80,800	71,791	75,28
b) Crop protection products	35,104	35,087	35,067	35,104	35,067	34,65
c) Unallocated	(42,734) 73,17 0	(42,295)	(41,742)	(42,734)		
Total capital employed		70,225	65,116	73,170	(41,742) 65,116	(42,998 66,93

Place : Mumbai

Date : 1 February 2019

Apodi Anis Cummune

M. M. J. P. J. Factoria

Mumpus-200011
India

TALLTO TO TO THE PARTY OF THE P

For HIKAL LTD

∠ — — Jai Hiremath

Chairman and Managing Director

DIN: 00062203

HIKAL LTD

Regd. Office: 717/718, Maker Chamber V, Nariman Point, Mumbai - 400 021.

Phone: +91-22-30973100, Fax: +91-22-30973281

CIN: L24200MH1988PTC048028, E Mail: info@hikal.com, Website: www.hikal.com

Just the right chemistry

BSR&Co.LLP

5th Floor, Lodha Excelus, Apollo Mills Compound

N. M. Joshi Marg, Mahalaxmi Mumbai - 400 011 India Telephone +91 (22) 4345 5300 Fax +91 (22) 4345 5399

Limited review report on Unaudited Quarterly Financial Results and Unaudited year-to-date results of Hikal Limited pursuant to Regulation 33 of the SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Hikal Limited

We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Hikal Limited ('the Company') for the quarter ended 31 December 2018 and the year-to-date results for the period from 1 April 2018 to 31 December 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 1 February 2019. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BSR & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

Farhad Bamji

Partner

Membership No: 105234

Mumbai 1 February 2019